Non-Hodgkin Lymphoma - Pipeline Review, H1 2017

  • ID: 4301789
  • Report
  • Region: Global
  • 1740 Pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • BeiGene Ltd
  • CTI BioPharma Corp
  • ImmunoGen Inc
  • Mirati Therapeutics Inc
  • Rhizen Pharmaceuticals SA
  • MORE

Non-Hodgkin Lymphoma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot), fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 28, 137, 124, 5, 123, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 15, 17, 16 and 4 molecules, respectively.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology).

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • BeiGene Ltd
  • CTI BioPharma Corp
  • ImmunoGen Inc
  • Mirati Therapeutics Inc
  • Rhizen Pharmaceuticals SA
  • MORE

Introduction
Non-Hodgkin Lymphoma - Overview
Non-Hodgkin Lymphoma - Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Drug Profiles
Non-Hodgkin Lymphoma - Dormant Projects
Non-Hodgkin Lymphoma - Discontinued Products
Non-Hodgkin Lymphoma - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Products under Development by Companies, H1 2017 (Contd..20), H1 2017
Products under Development by Companies, H1 2017 (Contd..21), H1 2017
Products under Development by Companies, H1 2017 (Contd..22), H1 2017
Products under Development by Companies, H1 2017 (Contd..23), H1 2017
Products under Development by Companies, H1 2017 (Contd..24), H1 2017
Products under Development by Companies, H1 2017 (Contd..25), H1 2017
Products under Development by Companies, H1 2017 (Contd..26), H1 2017
Products under Development by Companies, H1 2017 (Contd..27), H1 2017
Products under Development by Companies, H1 2017 (Contd..28), H1 2017
Products under Development by Companies, H1 2017 (Contd..29), H1 2017
Products under Development by Companies, H1 2017 (Contd..30), H1 2017
Products under Development by Companies, H1 2017 (Contd..31), H1 2017
Products under Development by Companies, H1 2017 (Contd..32), H1 2017
Products under Development by Companies, H1 2017 (Contd..33), H1 2017
Products under Development by Companies, H1 2017 (Contd..34), H1 2017
Products under Development by Companies, H1 2017 (Contd..35), H1 2017
Products under Development by Companies, H1 2017 (Contd..36), H1 2017
Products under Development by Companies, H1 2017 (Contd..37), H1 2017
Products under Development by Companies, H1 2017 (Contd..38), H1 2017
Products under Development by Companies, H1 2017 (Contd..39), H1 2017
Products under Development by Companies, H1 2017 (Contd..40), H1 2017
Products under Development by Companies, H1 2017 (Contd..41), H1 2017
Products under Development by Companies, H1 2017 (Contd..42), H1 2017
Products under Development by Companies, H1 2017 (Contd..43), H1 2017
Products under Development by Companies, H1 2017 (Contd..44), H1 2017
Products under Development by Companies, H1 2017 (Contd..45), H1 2017
Products under Development by Companies, H1 2017 (Contd..46), H1 2017
Products under Development by Companies, H1 2017 (Contd..47), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2017
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by ACEA Biosciences Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Aileron Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Alfa Wassermann SpA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Aptose Biosciences Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by ArQule Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Arven Ilac, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Arvinas Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2017
Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by BioAtla LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2017
Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by BioNTech AG, H1 2017
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Calimmune Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cascadian Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Celleron Therapeutics Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Celon Pharma SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Centrose LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cleave Biosciences Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SAS, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H1 2017
Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Curis Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by CytomX Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Debiopharm International SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Denovo Biopharma LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corp, H1 2017
Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Eisai Co Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2017
Non-Hodgkin Lymphoma - Pipeline by EpiZyme Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H1 2017
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Forma Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Forty Seven Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Galderma SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Genentech Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Genosco Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Heidelberg Pharma GmbH, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Humorigin Biotechnology Corp, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Hutchison China MediTech Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H1 2017
Non-Hodgkin Lymphoma - Pipeline by IGF Oncology LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Ignyta Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp, H1 2017
Non-Hodgkin Lymphoma - Pipeline by ImmunGene Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Immunomedics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Immunovaccine Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Immunwork Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Incyte Corp, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Japan Tobacco Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by JHL Biotech Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by K-Stemcell Co Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Klyss Biotech Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by LFB SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by MacroGenics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by MedImmune LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Medivir AB, H1 2017
Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by MENTRIK Biotech LLC, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Mesoblast Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Moleculin Biotech Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2017
Non-Hodgkin Lymphoma - Pipeline by NantKwest Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by NBE-Therapeutics AG, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2017
Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Oncobiologics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Oncopeptides AB, H1 2017
Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Oncovir Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by OXIS International Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Patrys Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Philogen SpA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by PIQUR Therapeutics AG, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Selvita SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Sierra Oncology Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau SpA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma KK, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Soligenix Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Sunesis Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Surface Oncology Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Targazyme Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Ltd, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by United BioPharma Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Verastem Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Xencor Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology Inc, H1 2017
Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc, H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..1), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..2), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..3), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..4), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..5), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..6), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..7), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..8), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..9), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..10), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..11), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..12), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..13), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..14), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..15), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..16), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..17), H1 2017
Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..18), H1 2017
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..1), H1 2017
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..2), H1 2017
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..3), H1 2017
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..4), H1 2017
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..5), H1 2017
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..6), H1 2017
Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..7), H1 2017

List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • ACEA Biosciences Inc
  • Actinium Pharmaceuticals Inc
  • ADC Therapeutics Sarl
  • Affimed GmbH
  • Affitech A/S
  • Aileron Therapeutics Inc
  • Alfa Wassermann SpA
  • Allinky Biopharma
  • Altor BioScience Corp
  • Amgen Inc
  • Angimmune LLC
  • Aptose Biosciences Inc
  • arGEN-X BV
  • Arno Therapeutics Inc
  • ArQule Inc
  • Arrien Pharmaceuticals LLC
  • Arven Ilac
  • Arvinas Inc
  • Asana BioSciences LLC
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Aurigene Discovery Technologies Ltd
  • Bayer AG
  • BeiGene Ltd
  • Bellicum Pharmaceuticals Inc
  • Bio-Path Holdings Inc
  • BioAtla LLC
  • Biocon Ltd
  • BioInvent International AB
  • BioLineRx Ltd
  • Bionovis SA
  • BioNTech AG
  • BioSight Ltd
  • Biothera Pharmaceutical Inc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Company
  • Calimmune Inc
  • Calithera Biosciences Inc
  • Cascadian Therapeutics Inc
  • Celgene Corp
  • Cell Medica Ltd
  • Cell Source Inc
  • Cell>Point LLC
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Cellectis SA
  • Celleron Therapeutics Ltd
  • Celltrion Inc
  • Cellular Biomedicine Group Inc
  • Celon Pharma SA
  • Centrose LLC
  • CerRx Inc
  • Chipscreen Biosciences Ltd
  • Cleave Biosciences Inc
  • Clevexel Pharma SAS
  • Coherus BioSciences Inc
  • Constellation Pharmaceuticals Inc
  • Cornerstone Pharmaceuticals Inc
  • CSPC Pharmaceutical Group Limited
  • CTI BioPharma Corp
  • Curis Inc
  • Cyclacel Pharmaceuticals Inc
  • CytomX Therapeutics Inc
  • Daiichi Sankyo Company Ltd
  • Debiopharm International SA
  • Denovo Biopharma LLC
  • Dynavax Technologies Corp
  • eFFECTOR Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • EpiZyme Inc
  • Erytech Pharma SA
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • Forma Therapeutics Inc
  • Formula Pharmaceuticals Inc
  • Forty Seven Inc
  • Galderma SA
  • Genentech Inc
  • Genor BioPharma Co Ltd
  • Genosco Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Grupo Ferrer Internacional SA
  • H3 Biomedicine Inc
  • Heidelberg Pharma GmbH
  • Humorigin Biotechnology Corp
  • Hutchison China MediTech Ltd
  • iDD biotech SAS
  • IGF Oncology LLC
  • Ignyta Inc
  • Immune Design Corp
  • ImmunGene Inc
  • ImmunoGen Inc
  • Immunomedics Inc
  • Immunovaccine Inc
  • Immunwork Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • Innate Pharma SA
  • Innovent Biologics Inc
  • Japan Tobacco Inc
  • JHL Biotech Inc
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • K-Stemcell Co Ltd
  • Kainos Medicine Inc
  • Karyopharm Therapeutics Inc
  • Kite Pharma Inc
  • Klyss Biotech Inc
  • Komipharm International Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • LFB SA
  • Mabion SA
  • MacroGenics Inc
  • MedImmune LLC
  • Medivir
  • AB
  • MEI Pharma Inc
  • MENTRIK Biotech LLC
  • Merck & Co Inc
  • Merck KGaA
  • Mesoblast Ltd
  • Millennium Pharmaceuticals Inc
  • miRagen Therapeutics Inc
  • Mirati Therapeutics Inc
  • Molecular Templates Inc
  • Moleculin Biotech Inc
  • Molplex Ltd
  • MorphoSys AG
  • NantKwest Inc
  • NBE-Therapeutics AG
  • Neumedicines Inc
  • Nordic Nanovector ASA
  • NovaLead Pharma Pvt Ltd
  • Novartis AG
  • NovImmune SA
  • Oncobiologics Inc
  • Onconova Therapeutics Inc
  • Oncopeptides AB
  • OncoSec Medical Inc
  • Oncovir Inc
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Onxeo SA
  • Oxford BioTherapeutics Ltd
  • OXIS International Inc
  • Patrys Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Philogen SpA
  • PIQUR Therapeutics AG
  • Polaris Pharmaceuticals Inc
  • Portola Pharmaceuticals Inc
  • RedHill Biopharma Ltd
  • Regeneron Pharmaceuticals Inc
  • Respiratorius AB
  • Rhizen Pharmaceuticals SA
  • Richter Gedeon Nyrt
  • Sandoz International GmbH
  • Sanofi
  • Sareum Holdings Plc
  • Seattle Genetics Inc
  • Selvita SA
  • Senhwa Biosciences Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shanghai Pharmaceutical Co Ltd
  • Sierra Oncology Inc
  • Sigma-Tau SpA
  • Simcere Pharmaceutical Group
  • Solasia Pharma KK
  • Soligenix Inc
  • Sorrento Therapeutics Inc
  • Spectrum Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • Sunesis Pharmaceuticals Inc
  • Supratek Pharma Inc
  • Surface Oncology Inc
  • Sutro Biopharma Inc
  • Taiho Pharmaceutical Co Ltd
  • Taiwan Liposome Company Ltd
  • Takara Bio Inc
  • Targazyme Inc
  • Teva Pharmaceutical Industries Ltd
  • TG Therapeutics Inc
  • Theravectys SA
  • TRACON Pharmaceuticals Inc
  • Transgene Biotek Ltd
  • Transgene SA
  • Trillium Therapeutics Inc
  • United BioPharma Inc
  • Unum Therapeutics Inc
  • Verastem Inc
  • Vivolux AB
  • Xencor Inc
  • Xenetic Biosciences Inc
  • ZIOPHARM Oncology Inc
  • Zymeworks Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll